NCT01051596View on ClinicalTrials.gov

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions

Colorectal Cancer

Interventions

DRUG

Temozolomide

150mg/m2 Days 1-5 of each 28 day cycle

DRUG

ABT-888

40mg orally BID Days 1-7 of each 28 day cycle

Trial Locations (1)

20008

Georgetown University Medical Center, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Abbott

INDUSTRY

lead

Georgetown University

OTHER